Drug Discovery

A Synthetic Lethal Drug Reaches Patients Seven Years After Its Target Was Found

The first WRN helicase inhibitor tested in humans held disease stable in three quarters of patients with microsatellite instability tumours, but shrank only one in ten.

Anam · Oct 18, 2026 · 7 min read

Neuroscience

An Enzyme That Rises With Age May Be Part of Why Some Brains Resist Decline

PLA2G2F climbs in ageing neurons, protects memory in mice when boosted, and is most active in people whose cognition survived amyloid pathology.

Anam · Oct 18, 2026 · 7 min read

Research & Development

An Automated Route From Bacterial Genome to Peptide, Without Synthetic DNA

A platform called OSAR assembled 31 of 34 large bacterial gene clusters and produced 29 peptides, turning a months-long bespoke process into a batch workflow.

Anam · Oct 18, 2026 · 7 min read

Regulatory Affairs

FDA Sets Out What It Will Disclose, and What Stays Redacted

The agency's Transparency Roadmap makes rejection letters standing practice and proposes disclosing that applications exist, but most of it remains intention rather than rule.

Anam · Oct 18, 2026 · 7 min read

Medical Devices

Sirolimus-Coated Balloon Beats Plain Angioplasty in First US Randomized Trial

SELUTION4SFA randomized 300 patients with narrowed leg arteries and met both its efficacy and safety endpoints, offering the field an alternative to paclitaxel.

Anam · Oct 18, 2026 · 7 min read

Digital Health

Two Trials Put Clinical AI to Work: One Explains, One Overspends

A randomized trial found AI-written summaries improved consultations and cut them by eight minutes. A companion study found AI-recommended care cost 3.2 times what physicians ordered.

Anam · Oct 17, 2026 · 7 min read

Clinical Trials

When the Standard of Care Moves: What CARDIO-TTRansform Reveals About Trial Design

Eplontersen missed its primary endpoint in 1,432 patients with amyloid cardiomyopathy, yet slowed functional decline. The explanation lies in what patients were already taking.

Anam · Oct 17, 2026 · 7 min read

Biotechnology

In Vivo CAR-T: First Clinical Data Show It Works, but Not for Long

Two October papers pull together every trial of CAR T-cells made inside the body: 41 patients, responses in all four myeloma cases, and a median progression-free survival of four months.

Anam · Oct 17, 2026 · 7 min read

Research & Development

Roche Bets on Molecular Glue Degraders in Discovery Deal With China's Defand

Roche will pay Hangzhou-based Defand to screen for molecular glue degraders in cancer and immunology, a sign of growing interest in drugs that destroy proteins rather than block them.

Anam · Oct 17, 2026 · 7 min read

Regulatory Affairs

FDA Launches Rare Disease Framework to Tailor Evidence for Small Populations

A new white paper sets out a fit-for-purpose approach to reviewing rare disease drugs and biologics, from pre-IND meetings through manufacturing and post-approval obligations.

Anam · Oct 17, 2026 · 7 min read

Digital Health

FDA Clears First MRI-Based AI Tool for Breast Cancer Recurrence Risk

TumorSight Risk combines a diagnostic breast MRI with five clinical factors to estimate 5- and 10-year recurrence risk in HR-positive, HER2-negative early breast cancer.

Anam · Oct 17, 2026 · 7 min read

Oncology

FDA Approves Pirtobrutinib for Previously Untreated CLL and SLL

The first non-covalent BTK inhibitor moves to first-line use after BRUIN CLL-313 showed an 80% cut in the risk of progression or death versus bendamustine-rituximab.

Anam · Oct 17, 2026 · 7 min read